hsa-mir-106a: Hsa-mir-106a is a microRNA that is involved in the regulation of gene expression [PMC7770216]. According to a study by Zhang et al., it was found that HPV E7/DGCR8 inhibits the expression of RUNX3 and enhances radiation sensitivity by promoting the expression of hsa-mir-106a [PMC7770216]. In another study by Liang et al., it was observed that hsa-mir-106a has a reverse pattern of expression compared to its target genes BDH1, UPP1, TUSC2, and KMO in the short-term survival group [PMC3852212]. These target genes were found to be over-expressed in the short-term survival group [PMC3852212].

MIR106A: MIR106A is a microRNA that has been shown to inhibit the target gene MMP2 through transfection [PMC9692470]. The relevance of NFκB and AP-1 transcription factors binding to the miR-106a promoter in response to TNFα signaling was investigated using luciferase assays with a full-length MIR106A construct [PMC6301105]. The study utilized a NFκB inhibitor, Bay 11–7082, and an AP-1 false substrate, c-JUN peptide, in the presence of TNFα [PMC6301105]. The diagnostic performance of MIR106A in colorectal cancer (CRC) was found to be relatively high based on the summary DOR and the area under SROC [PMC5354890]. In a study on aortic aneurysm, circulating miR-17 and miR-20a showed an inverse linear correlation with the maximum aortic diameter, while other microRNAs including MIR106A did not show significance in this regard [PMC7020030]. Additionally, it was found that miR20a and MIR106A negatively regulated WTX expression [PMC6328557]. Overall, these findings highlight the role of MIR106A in gene regulation and its potential diagnostic significance in CRC.